National Cancer Institute, Research Contracts Branch, PSCS, 6120 Executive Blvd, Eps/room 638, Bethesda, MD 20892-7227

B -- ASSAYS TO DETERMINE C-PEPTIDE AND FRUCTOSAMINE LEVELS SOL RFQ70197-NS DUE 091697 POC Patricia Haun, Contracting Officer 301-496-8613 This is a combined synopsis/solicitation for assays to determine c- peptide and fructosamine levels in 627 serum samples. The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) plans to procure these assays on a sole source basis, under authority of FAR 6.302-1, from Quest Diagnostics Inc., 33608 Ortega Hgwy., San Juan Capistrano, CA 92690. The 627 samples reflect 190 breast cancer cases, 190 cases with hyperplastic benign breast disease, 190 benign controls with non-hyperplastic beast disease, and 57 quality control samples. DCEG has only about 0.8ml of the serum available for both assays after retaining a necessary portion for potential follow-up testing. Quest Diagnostics can perform both assays with this amount of the serum, and is the only source known to NCI that can do so. This notice of intent is not a request for competitive proposals, however, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. Information furnished must be in writing and must contain sufficient detail to allow NCI to determine if the party can perform the requirement. Information must be received within 15 days of the publication of this notice. See Note 22. (0245)

Loren Data Corp. http://www.ld.com (SYN# 0009 19970904\B-0002.SOL)